|Related Categories||Angiotensin Receptor Antagonists, Approved Therapeutics/Drug Candidates, Bioactive Small Molecules, Biochemicals and Reagents, Boehringer Ingelheim,|
|solubility||DMSO: >5 mg/mL at 60 °C|
Telmisartan is a non-peptide AT1 angiotensin receptor antagonist.
Telmisartan is soluble in DMSO at a concentration that is greater than 5 mg/ml. It is insoluble in water.
Telmisartan has been used as an AT1 receptor antagonist to study its effects on mouse models of myocardial infarction. This study reported that telmisartan inhibited the CCN1 upregulation and reduced CCN2 levels atrial cardiomyocytes1. Telmisartan has also been used to evaluate its effect on the expression of CCN1 in kidney cortex of mice subjected to myocardial infarction2. Furthermore, telmisartan has been used to test its efficacy against tumor growth in mouse models of colorectal cancer3.
Different receptors/binding sites have been identified for the biologically active angiotensin (Ang) peptides, i.e. Ang II (1-8), Ang III (2-8), Ang IV (3-8) and Ang (1-7), based on the availability ...
Keywords: Atomic absorption spectroscopy, Cardiovascular, Catalysis, Cell proliferation, Gene expression, Ligands, Metabolites, Transduction
Download BioFiles v7 n5 (3.18 Mb PDF) Back to Pharmaceutical Drugs and Drug Candidates homepage
BioFiles v7 n5, 2012, 5–20
Keywords: AGE, Antihypertensives, Cardiovascular, Clinical, Diuretics, Pharmaceutical, Reductions
Novel description of the 24-hour circadian rhythms of brachial versus central aortic blood pressure and the impact of blood pressure treatment in a randomized controlled clinical trial: The Ambulatory Central Aortic Pressure (AmCAP) Study. Williams B, Lacy PS, Baschiera F, et al. Hypertension 61(6), 1168-76, (2013)
Abnormal amounts of intracellular calcium regulatory proteins in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome and cardiac dysfunction. Kagota S, Maruyama K, Tada Y, et al. Can. J. Physiol. Pharmacol. 91(2), 124-33, (2013)
Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. Dehghan M, Mente A, Teo KK, et al. Circulation 126(23), 2705-12, (2012)
Ameliorative effects of telmisartan on the inflammatory response and impaired spatial memory in a rat model of Alzheimer's disease incorporating additional cerebrovascular disease factors. Shindo T, Takasaki K, Uchida K, et al. Biol. Pharm. Bull. 35(12), 2141-7, (2012)
Pharmacokinetics, pharmacodynamics and toxicity of a combination of metoprolol succinate and telmisartan in Wistar albino rats: safety profiling. Nandi U, Karmakar S, Das AK, et al. Regul Toxicol Pharmacol 65(1), 68-78, (2013)
A comparative pharmacokinetic study of a fixed dose combination for essential hypertensive patients: a randomized crossover study in healthy human volunteers. Gorain B, Choudhury H, Halder D, et al. Drug Res. (Stuttg.) 63(4), 177-84, (2013)
Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-γ. Casimiro-Garcia A, Heemstra RJ, Bigge CF, et al. Bioorg. Med. Chem. Lett. 23(3), 767-72, (2013)
Telmisartan, an AT1 receptor blocker and a PPAR gamma activator, alleviates liver fibrosis induced experimentally by Schistosoma mansoni infection. Attia YM, Elalkamy EF, Hammam OA, et al. Parasit. Vectors 6, 199, (2013)
Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and type 2 diabetic rats. Olverling A, Huang Z, Nyström T, et al. Clin. Sci. 125(9), 433-8, (2013)
A pilot study of telmisartan for visceral adiposity in HIV infection: the metabolic abnormalities, telmisartan, and HIV infection (MATH) trial. Lake JE, Tseng CH, and Currier JS PLoS ONE 8(3), e58135, (2013)
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials. Takagi H, Mizuno Y, Yamamoto H, et al. Hypertens. Res. 36(4), 368-73, (2013)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Need larger quantities for your development, manufacturing or research applications?